News

A report is claiming that patients with type I diabetes living in the UK are being denied the opportunity to take part in clinical research.

Sir David Nicholson, outgoing chief executive of the NHS England, has called for a new strategy for the future of the NHS that will help it side-step electoral tyranny, instil a positive culture, and better weather media storms.

Questcor’s stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis’ rival immune drug Synacthen.

The US Food and Drug Association has approved Sanofi’s supplemental biologics license application for Fluzone Quadrivalent, which the company says is the first-and-only four-strain influenza vaccine for patients as young as six months of age.

A picture of huge variation in avoidable deaths in England has been unveiled by a new website launched this week by Public Health England (PHE).

Medical Research Network (MRN), the UK-based provider of home-healthcare and site-support services for clinical trials, is launching a new patient-recruitment tool claimed to offer “unrivalled planning” in the run-up to study starts.

New research from the University of Southampton provides the first direct evidence that a widespread policy of employing more specialist nurses in hospitals is linked to measurable benefits for patients, say the authors.

Five new university and business partnerships are to be given nearly £300 million of public and private investment in research projects.

Almost a year after getting approval, Arena Pharmaceuticals’ weight loss drug Belviq will be launched this week in the USA by partner Eisai.

AstraZeneca has hit the acquisition trail again to buy US firm Pearl Therapeutics, which focuses on the development of inhaled drugs for respiratory disease.

In the latest chapter of the battle for control of Elan Corp, the Irish drugmaker has rejected a third increased offer from Royalty Pharma but noted that it has hired an advisor to look at other offers.

Gilead Sciences has been boosted by the news that regulators in the USA have granted a priority review to its investigational hepatitis C pill sofosbuvir.

New research shows that by 2020 almost one in two people will get cancer in their lifetime, but 38% will not die from the disease.

Apricus Biosciences of the USA says that Vitaros, its topically-applied cream formulation of alprostadil, has been approved for erectile dysfunction in 10 European countries.

The European Medicines Agency has expanded approval for Roche’s RoActemra to cover the treatment of children with polyarticular juvenile idiopathic arthritis.